Document is current
Any future updates will be listed below
-
Authors
Desman, Jacob M.
Hong, Zhang-Wei
Sabounchi, Moein
Sawant, Ashwin S.
Gill, Jaskirat
Costa, Ana C.
Kumar, Gagan
Sharma, Rajeev
Gupta, Arpeta
McCarthy, Paul
Nandwani, Veena
Powell, Doug
Carideo, Alexandra
Goodwin, Donnie
Ahmed, Sanam
Gidwani, Umesh
Levin, Matthew A.
Varghese, Robin
Filsoufi, Farzan
Freeman, Robert
Shetreat-Klein, Avniel
Charney, Alexander W.
Hofer, Ira
Chan, Lili
Reich, David
Kovatch, Patricia
Kohli-Seth, Roopa
Kraft, Monica
Agrawal, Pulkit
Kellum, John A.
Nadkarni, Girish N.
Sakhuja, Ankit
-
Funding
Funding for this research was provided by:
NIH/NIDDK (5K08DK131286)
- License Information
-
More Information
Article History
Received: 10 December 2024
Accepted: 8 May 2025
First Online: 27 May 2025
Competing interests
: GLUCOSE is the subject of a provisional patent application (Application No. 63/698,447) filed with the United States Patents and Trademarks Office, in which JMD, AS, and GNN are named inventors. G.N.N. is a founder of Renalytix, Pensieve, Verici and provides consultancy services to AstraZeneca, Reata, Renalytix, Siemens Healthineer and Variant Bio, serves a scientific advisory board member for Renalytix and Pensieve. He also has equity in Renalytix, Pensieve and Verici. GNN is also an Associate Editor for npj Digital Medicine. He had no role in editorial decisions about the manuscript. L.C. is a consultant for Vifor Pharma INC and has received honorarium from Fresenius Medical Care. J.A.K. reports receiving consulting fees from Astute Medical/bioMerieux, Astellas, Alexion, Chugai Pharma, Novartis, Mitsubishi Tenabe and GE Healthcare and is a full time employee of Spectral Medical. All remaining authors have declared no conflicts of interest.
